Karo Bio's eprotirome could add to statin benefits
This article was originally published in Scrip
Executive Summary
Karo Bio's novel, selective, thyroid hormone receptor agonist, eprotirome, could become an attractive add-on to statin therapy for patients with dyslipidaemia, data from a Phase II trial suggest.